Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose
study in male and female patients ages 50 to less than 89 years with mild to moderate AD.
Approximately 230 study sites in the US and Canada and up to 35 sites outside of North
America will be involved. Patients will be randomized to receive either bapineuzumab or
placebo. Each patient's participation will last approximately 1.5 years.
Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid
peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Phase:
Phase 3
Details
Lead Sponsor:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC